cushing syndrome
Always exclude exogenous glucocorticoids (oral, inhaled, intra-articular, topical, ritonavir-boosted) first. Confirm endogenous hypercortisolism with two concordant positive screening tests (1-mg overnight DST, ≥2× 24-h UFC, or ≥2× late-night salivary cortisol) before measuring ACTH or ordering imaging. Once ACTH-dependent disease is confirmed, pituitary MRI lesions <6 mm require IPSS, whereas lesions ≥10 mm do not. Never order random cortisol, random ACTH, or an 8-mg DST as a screening test.
who to test (ES 2008)
- Most discriminatory signs: easy bruising, facial plethora, proximal myopathy, violaceous striae (>1 cm wide, especially abdominal/axillary)
- Test in:
- Unusual features for age (e.g., young-onset osteoporosis, vertebral fractures, resistant hypertension)
- Multiple progressive features compatible with hypercortisolism
- Every adrenal incidentaloma (for mild autonomous cortisol secretion [MACS] or overt Cushing syndrome)
- Do not screen unselected patients with isolated obesity, hypertension, or type 2 diabetes
- Exclude pseudo-Cushing (non-neoplastic hypercortisolism): severe depression, alcohol use disorder, uncontrolled diabetes, severe obesity, pregnancy, acute physiological stress
step 1 — confirm hypercortisolism
Require two concordant abnormal results from the three first-line tests (at least two collections for UFC or LNSC) before localising the source:
| test | protocol | positive threshold | key pitfalls / special populations |
|---|---|---|---|
| 1-mg overnight DST | 1 mg dexamethasone PO at 23:00–24:00; serum cortisol at 08:00–09:00 | cortisol >50 nmol/L | false positive: oral oestrogen (high CBG), CYP3A4 inducers (phenytoin, carbamazepine, rifampin — check serum dexamethasone level), poor absorption; avoid in pregnancy and enzyme-inducing AEDs; preferred in severe CKD and adrenal incidentaloma |
| 24-h urine free cortisol (UFC) | ≥2 complete 24-h collections (verify urine Cr and volume) | >ULN for assay | preferred in pregnancy; false negative if CrCl <60 mL/min; false positive with high urine volume (>5 L/d) or pseudo-Cushing |
| late-night salivary cortisol (LNSC) | ≥2 samples at 23:00–24:00 (passive drool or swab) | >ULN (typically >4 nmol/L, assay-specific) | measures free cortisol (unaffected by oral oestrogen/CBG); unreliable in shift workers, blood contamination, topical hydrocortisone, or smoking/chewing tobacco |
- Never use random serum cortisol, random ACTH, or 8-mg DST to diagnose Cushing syndrome
- Suspected cyclic Cushing: use repeated LNSC or UFC during symptomatic phases rather than DST; document active hypercortisolism immediately before dynamic testing or IPSS
step 2 — localise the source
Only after biochemical hypercortisolism is confirmed, measure morning plasma ACTH (repeat if borderline):
Confirmed hypercortisolism
├── ACTH suppressed (<2 pmol/L) ──► ACTH-independent (adrenal)
│ └── Dedicated adrenal CT (adenoma, carcinoma, bilateral hyperplasia)
│
└── ACTH unsuppressed / elevated (>4–5 pmol/L) ──► ACTH-dependent
└── Dedicated pituitary MRI (thin-slice, gadolinium)
├── Lesion ≥10 mm (+ concordant dynamic testing) ──► Cushing disease (IPSS not required)
├── Lesion <6 mm or normal MRI ──► Bilateral IPSS (gold standard to separate pituitary vs ectopic)
└── Lesion 6–9 mm ──► Expert judgement (IPSS often performed given high incidentaloma rate)
- Pituitary Society 2021 updates:
- IPSS (central-to-peripheral ACTH gradient) is the gold standard to differentiate pituitary Cushing disease from ectopic ACTH (e.g., bronchial carcinoid, small-cell lung cancer, pancreatic/thymic NET); never use IPSS to diagnose hypercortisolism (overlaps with healthy controls and pseudo-Cushing), and always verify the patient is actively hypercortisolaemic at the time of IPSS
- 8-mg high-dose DST is no longer routinely recommended due to poor specificity and frequent discordance; CRH or desmopressin stimulation plus pituitary MRI and thin-slice chest/abdomen/pelvis CT can assist non-invasively when ectopic ACTH is suspected (e.g., male with severe hypokalaemia and markedly elevated UFC)
- Ectopic ACTH clues: rapid onset, severe proximal myopathy, profound hypokalaemia (cortisol saturates renal 11β-HSD2 and activates mineralocorticoid receptors), marked hyperpigmentation, high ACTH and very high UFC
management and perioperative care (2021 consensus)
- First-line therapy = surgical resection of the causative lesion by an experienced surgeon:
- Cushing disease: transsphenoidal resection (remission ~70–85% for microadenomas)
- Adrenal adenoma: laparoscopic unilateral adrenalectomy (see adrenal incidentaloma for MACS)
- Ectopic ACTH: resect primary tumour if localised
- Post-operative adrenal insufficiency: successful resection suppresses the remaining HPA axis — give perioperative glucocorticoid coverage and monitor morning cortisol (post-op nadir <55 nmol/L defines remission, though late recurrence still requires long-term surveillance); taper physiologic hydrocortisone slowly over months until HPA recovery
- Medical therapy (bridge to surgery in severe hypercortisolism, persistent/recurrent disease, or non-surgical candidates):
- Adrenal steroidogenesis inhibitors: ketoconazole, metyrapone, osilodrostat (monitor LFTs, QTc, hypokalaemia, adrenal insufficiency)
- Pituitary-directed (Cushing disease): pasireotide (high risk of hyperglycaemia), cabergoline
- Glucocorticoid receptor antagonist: mifepristone (blocks cortisol action — cortisol/ACTH remain elevated, so monitor clinically and for hypokalaemia/endometrial thickening)
- Refractory severe disease: pituitary radiotherapy or bilateral adrenalectomy (monitor for Nelson syndrome — corticotroph tumour progression and hyperpigmentation)
- Comorbidity and complication prophylaxis:
- VTE prophylaxis: Cushing syndrome is strongly prothrombotic (risk peaks peri-operatively and persists for weeks post-op); give perioperative pharmacologic VTE prophylaxis (Pituitary Society 2021)
- Opportunistic infection: consider Pneumocystis jirovecii (PJP) prophylaxis in severe hypercortisolism (markedly elevated UFC)
- Treat hypertension, hyperglycaemia, hypokalaemia, and osteoporosis aggressively
An adrenal incidentaloma with 1-mg DST cortisol >50 nmol/L without overt Cushing stigmata is MACS (ESE 2023). It carries excess risk of hypertension, diabetes, and vertebral fractures — manage comorbidities aggressively, consider surgery in selected patients, and always give perioperative stress steroids if resected.
Prepared 2026-11-19. Not yet verified — check every number against the sources.